Literature DB >> 2297456

Effects of aspirin upon the flushing reaction induced by niceritrol.

R H Jay1, A C Dickson, D J Betteridge.   

Abstract

The usefulness of niceritrol as a lipid-lowering agent is limited by a prostaglandin-mediated flushing reaction after each dose occurring in the early stages of treatment. We have tested the effect of premedication with aspirin on the reaction to 250 mg niceritrol in 30 healthy male volunteers using both subjective and observed assessments of severity. Both 300 mg and 600 mg of aspirin significantly reduced the severity of flushing when compared with placebo. No significant difference was seen between the two dose levels. Prior dosing with aspirin may increase acceptability of niceritrol and hence improve compliance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2297456      PMCID: PMC1380070          DOI: 10.1111/j.1365-2125.1990.tb03611.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  Clinical and metabolic effects of pentaerythritol tetranicotinate(Perycit)and a comparison with plain nicotinic acid.

Authors:  A G Olsson; L Orö; S Rössner
Journal:  Atherosclerosis       Date:  1974 Jan-Feb       Impact factor: 5.162

2.  Pentaerythritoltetranicotinate (Perycit) in the treatment of hypercholesterolaemia.

Authors:  K Sigroth
Journal:  Acta Med Scand       Date:  1968-10

3.  Aspirin all round?

Authors:  M Orme
Journal:  Br Med J (Clin Res Ed)       Date:  1988-01-30

4.  Aspirin blocks nicotinic acid-induced flushing.

Authors:  J K Wilkin; O Wilkin; R Kapp; R Donachie; M E Chernosky; J Buckner
Journal:  Clin Pharmacol Ther       Date:  1982-04       Impact factor: 6.875

5.  The effects on lipids, blood viscosity and platelet aggregation of combined use of niceritrol (Perycit) and a low dose of acetylsalicylic acid.

Authors:  T Hamazaki; K Hasunuma; S Kobayashi; H Shishido; S Yano
Journal:  Atherosclerosis       Date:  1985-04       Impact factor: 5.162

  5 in total
  1 in total

Review 1.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.